Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.
ON THE RADAR: M&A DEALS, LUXURY AND ASTRAZENECA (0635 GMT)
Futures point to gains for European bourses this morning as global sentiment is quite upbeat
on hopes for a COVID-19 vaccine and treatment, as well as on renewed confidence in a China-U.S.
trade deal.
But GDP data from Germany may cap these gains. The euro zone largest economy contracted by a
record 9.7% in the Q2 as private consumption, investments and exports all collapsed at the
height of the COVID-19 pandemic, the statistics office said in a minor upward-revision to an
earlier estimate.
In terms of corporate headlines, there is a couple of interesting ones around luxury M&A
with French giant LVMH and U.S. jewellery chain Tiffany giving themselves
another three months to complete their $16.2 billion tie-up after the deal did not close on the
Aug. 24 date set out in deal documents, a person familiar with the matter said.
While spectacles maker EssilorLuxottica said it may appeal against an earlier
court verdict regarding its planned takeover target GrandVision, after it lost a Dutch
court case which could jeopardise the deal.
AstraZeneca started early stage trials for an antibody-based treatment for the
prevention and treatment of COVID-19, as the British drugmaker also ploughs on with its vaccine
candidate.
Meantime, British software company Aveva Group reached a deal to buy U.S.-based
real-time industrial data software and services provider OSIsoft for $5 billion.
In the banking space, Credit Suisse intends to generate 100 million Swiss francs
($110 million) in annual savings by merging subsidiaries in the canton of Aargau and cutting the
number of branches in favour of more digital bank.
Staying in Switzerland, the competition watchdog has launched an investigation into Swisscom
, which is accused of charging excessively high prices in its tenders for projects to
connect company sites.
(Joice Alves)
*****
MORNING CALL: WE HAVE IT ALL (0540 GMT)
Meaning China-U.S. trade deal talks, Germany GDP data, treatment hopes and COVID-19 fears,
all weighing on markets sentiment this morning.
As a result, European bourses are seen opening higher, on track for a second day of gains as
renewed confidence in a China-U.S. trade deal after talks between the countries and fresh
vaccine helped lift the mood.
Asian stocks rose following reports that top U.S. and Chinese officials see progress in
resolving concerns around the Phase 1 trade deal reached between the two countries in January.
Markets have also been supported by optimism about medical solutions to end the coronavirus
pandemic, including the use of the blood plasma from recovered patients as treatment.
That seemed to overshadow a rise in cases in Europe and the first documented case of
re-infection, where a man in Hong Kong caught the virus twice.
Meantime, Germany Q2 GDP and IFO Business Climate survey are due today.
"Today’s latest iteration of Germany’s latest Q2 GDP revision is expected to affirm how
badly the German economy fared as a result of the lockdown period," writes Michael Hewson, chief
market analyst at CMC Markets UK
Financial spreadbetters at IG expect London's FTSE to open 16 points higher at 6,121,
Frankfurt's DAX to open 86 points higher at 13,152 and Paris' CAC to open 25 points higher at
5,033.
(Joice Alves)
*****
Astrazeneca (AZN)
